Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-444 Patient Experience Study in Dry Eye Disease
NCT05878067Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Primary completion
- Oct 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ABBV-444 in dry eye disease (DED), sponsored by AbbVie Inc. Primary endpoint: Ocular Surface Disease Index at Day 30. Started Jun 2023; status: completed.
02
Drugs
ABBV-444
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05878067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878067.